Nova Patents
CA2662340C

Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Abstract

The present invention provides chimeric and humanized versions of anti-CD 19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD 19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft- versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

CA2662340C, drawing sheet 1
Sheet 1 of 25

Term

1 yearleft in the term

Expires 7 September 2027.

  1. Priority
  2. Filed
  3. Granted
  4. Today
  5. Expires

13 claims: 5 independent, 8 dependent

  1. 1
    CA 02662340 2015-05-14 51332-52 CLAIMS:1. An isolated purified humanized monoclonal antibody or fragment thereof comprising a VH comprising an amino acid sequence of SEQ ID NO.:106 and a VL domain comprising an amino acid sequence of SEQ ID NO.: 111, wherein said antibody binds a human CD 19 antigen.
  2. 8
    An isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO:106 or SEQ ID NO: 111.
  3. 9
    An isolated cell expressing the antibody of any one of claims 1 to 7.
  4. 10
    A pharmaceutical composition comprising the antibody of any one of claims 1 5 to 7 in a pharmaceutically-acceptable carrier.
  5. 11
    A therapeutically-effective amount of an antibody of any one of claims 1 to 7 for use for treating a B cell disease or disorder in a human, wherein said disease or disorder is selected from a group consisting of:B cell malignancy, autoimmune disease, autoimmune disorder, humoral rejection in a human transplant patient, graft-versus-host disease (GVHD) 10 and post-transplantation lymphoproliferative disorder in human transplant recipient.
Independent claims5